Journal's Scope

New Approaches combating Cancer & Aging (NACA) focuses on rapid publication of novel concept, methods, instruments, and regimes for detection, intervention, and prevention of cancer and aging, which are closely associated events. The following types of articles are particularly welcomed.
  1. Original research and short research communication
  2. Review and mini-review
  3. Novel medical hypothesis
  4. Novel therapeutic protocols
  5. Novel research methods
  6. New equipment, reagents, and biomarkers
  7. Commentary and letter to the editor –in-chief
  8. Author-initiated special issues
Journal's 4-A-Features
  1. An author-friendly manuscript submission system
    • The online submission process can be completed within 5-7 minutes
    • NACA encourages authors to choose their preferred format for manuscript submission
    • NACA encourages authors to make the design and display for their accepted papers
    • NACA provides free language editing to authors who’s native language is not English
  2. A fast review and publication process
    • A decision for the submission can be made within 3-weeks after the reception by NACA
    • Major grant-supported manuscripts can be published within 2-weeks after the submission
    • Authors can request publication of rejected papers with reviewers' comments for debate
    • NACA publishes selective articles in both English and Chinese side-by-side
  3. A strong sponsorship and wide readership
    • NACA is sponsored by the International Union for Difficult-to-treat-Diseases (IUDD; www.iudd.org), a non-profit international medical organization closely associated with medical professionals, patients, pharmaceutic and biologic manufacturers, researches, and governmental officers.
    • NACA is also sponsored by Chinese National Center of Colorectal Diseases, 3rd Affiliated Hospital of Nanjing Chinese Medical University, and Nanjing Health Bureau, China, an internationally known institute for its significant contributions to detection, intervention, and prevention of colorectal cancer
  4. Academic and financial awards to top-cited publications and promising projects
    • The top 5-most cited papers of the year will receive an academic certificate from IUDD and NACA
    • The corresponding author of the top 3-most cited papers will receive financial assistance to attend IUDD annual conference
    • Promising therapeutics or methodologies will be posted at the website of IUDD
    • Promising initiatives with significant scientific and clinical applications may receive financial support from IUDD
Editor-in-chief’s Short Profile

Yan-gao Man, MD, PhD
Director, Research Laboratory and International Collaboration, Bon Secours Cancer Institute, Bon Secours Health System, Richmond, VA, USA (with 20-hospitals and over 22,000 medical staff members)
Adjunct Senior Scientist, Hackensack University Medical Center, NJ, USA (one of 100 best US hospitals)
Vice President for Research and Collaboration, South Hospital of Nanjing, Nanjing, China
Visiting Professor, Chinese National Medical Center of Colorectal Diseases, Nanjing, China
Visiting Professor, Hunan Agriculture University, Changsha, China
Consultant, The Health System of the Hunan Province, China
Chairman of the Board and Secretary General
International Union for Difficult-to-treat Diseases (www.iudd.org)
Editor-in-chief, Journal of Cancer (Established in 2010; Impact factor 2.639)
Phone & Fax: 301-879-0816; 202-308-6317;
E-mail: yanmann@aol.com; yman@jcancer.org; yangao_man@bshsi.org; yangao_man@iudd.org

Dr. Man’s research is focused mainly on the mechanisms of tumor invasion and metastasis. He is the author of the world most updated theory for tumor invasion[1-2], which has been recognized as more compatible with the existing evidence than the traditional “proteolytic enzyme theory” [3]. He is also the author of the world most updated theory for tumor metastasis [4, 5]. Among existing theories, his theory is the only one that can reasonably explain all major events of tumor metastasis.

  1. Man YG. Focal degeneration of aged or injured myoepithelial cells and the resultant auto- immunoreactions are trigger factors for breast
  2. tumor invasion. Medical Hypotheses 69(6):1340-1357, 2007.
  3. Man YG, et al. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: Existing theories. J Cancer. 4(1): 84-95, 2013
  4. Pandey PR. Et al. (2011) Role of myoepithelial cells in breast tumor progression. Front Biosci, 15, 226–236, 2011.
  5. Man YG, et al. Leukocyte–facilitated tumor dissemination: findings from multiple types of human tumors. J Cell Chem.112(4):1154- 1167, 2011.
  6. Man YG, et al. Contributions of leukocytes to tumor invasion and metastasis: the “piggy-back” hypothesis. Cancer Epidem 34(1): 3-6, 2010.

Heiying Jin, MD, PhD
Professor of Surgery and Doctoral supervisor
Associated Director of National Centre of Colorectal Disease,
The T>hird affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
Phone: 025-52276200;
Email: jinheiying@hotmail.com; heijying_jin@iudd.org

Dr. Jin is a world-top-ranked surgical oncologist, researcher, and educator. His research is focused mainly on hereditary non-polyposis colorectal cancer (HNPCC), and also on the early detection, intervention, and prevention of colorectal cancer. He has been actively conducting a variety of innovative research projects with over 20-patents.

  1. Heiying Jin, et al. The study of effect of tea polyphenols on microsatellite instability colorectal cancer and its molecular mechanism. Int J Colorectal Dis (2010) 25:1407–1415, 2010.
  2. Heiying Jin, et al. A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor. Tumor Biol, Nov. 2010. Epub.
  3. Heiying Jin, et al. Downregulation of AP-1 gene expression is an initial eventin the oridonin-mediated inhibition of colorectal cancer:Studies in vitro and in vivo. J Gastroentology Hepotology, 2010, Epub